Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Autoimmunity Highlights
Published in: Autoimmunity Highlights 1/2017

Open Access 01-12-2017 | Review Article

The universe of ANA testing: a case for point-of-care ANA testing

Authors: Konstantin N. Konstantinov, Robert L. Rubin

Published in: Autoimmunity Highlights | Issue 1/2017

Login to get access

Abstract

Testing for total antinuclear antibodies (ANA) is a critical tool for diagnosis and management of autoimmune diseases at both the primary care and subspecialty settings. Repurposing of ANA from a test for lupus to a test for any autoimmune condition has driven the increase in ANA requests. Changes in ANA referral patterns include early or subclinical autoimmune disease detection in patients with low pre-test probability and use of negative ANA results to rule out underlying autoimmune disease. A positive result can lead to further diagnostic considerations. Currently, ANA tests are performed in centralized laboratories; an alternative would be ANA testing at the clinical point-of-care (POC). By virtue of its near real-time data collection capability, low cost, and ease of use, we believe the POC ANA has the potential to enable a new paradigm shift in autoimmune serology testing.
Literature
1.
Meroni PL, Biggioggero M, Pierangeli SS, Sheldon SS, Zegers I, Borghi MO (2014) Standardization of autoantibody testing: a paradigm for serology in rheumatic diseases. Nat Rev Rheumatol 10:35–43CrossRefPubMed
2.
3.
Mirzayan MJ, SchmidtnRE Witte T (2000) Prognostic parameters for flare in systemic lupus erythematosus. Rheumatology (Oxford) 39:1316–1319CrossRef
4.
5.
Bootsma H, Spronk P, Derksen RH, de Boer G, Wolters-Dicke H, Hemans J, Limburg P, Gmelig-Meyling F, Kater L, Kallenberg C (1995) Prevention of relapses in systemic lupus erythematosus. Lancet 345:1595–1599CrossRefPubMed
6.
7.
Freedman DB (2015) Toward better test utilization—strategies to improve physician ordering and their impact on patient outcomes. EJIFCC 26:15–30PubMedPubMedCentral
8.
Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, Herold M, Bossuyt X, Musset L, Cervera R et al (2014) International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis 73:17–23CrossRefPubMed
9.
10.
Forrest CB, Nutting PA, von Schrader S, Rohde C, Starfield B (2006) Primary care physician specialty referral decision making: patient, physician, and health care system determinants. Med Decis Mak 26:76–85CrossRef
11.
Fritzler MJ (2016) Choosing wisely: review and commentary on anti-nuclear antibody (ANA) testing. Autoimmune Rev 15:272–280CrossRef
12.
Kassamali A, Houle S, Rosenthal M, Tsuyuki R (2011) Case finding: the missing link in chronic disease management. Can Pharm J/RPC 144:170–172CrossRef
13.
14.
Bizzaro N, Tozzoli R, Shoenfeld Y (2007) Are we at a stage to predict autoimmune rheumatic diseases? Arthritis Rheum 56:1736–1744CrossRefPubMed
15.
Rolfe A, Burton C (2013) Reassurance after diagnostic testing with a low pretest probability of serious disease: systematic review and meta-analysis. JAMA Intern Med 173:407–416CrossRefPubMed
16.
17.
18.
Poo EG, Gandhi TK, Sequist TD, Murff HJ, Karson AS, Bates DW (2004) “I wish I had seen this test result earlier” Dissatisfaction with test results management system in primary care. Arch Intern Med 164:2223–2228CrossRef
19.
Konstantinov KN, Tzamaloukas A, Rubin RL (2013) Detection of autoantibodies in a point-of-care rheumatology setting. Autoimmun Highlights 4:55–61CrossRef
20.
Rubin RL, Konstantinov KN (2016) Biosensor for total antinuclear antibody determination at the point-of-care. Biosens Bioelectron 83:306–311CrossRefPubMed
21.
Mahler M, Hanly JG, Fritzler MJ (2012) Importance of the dense speckled pattern on HEp-2 cells and anti-DFS70 antibodies for the diagnosis of systemic autoimmune diseases. Autoimmun Rev 11:642–645CrossRefPubMed
22.
Yazdany J, Schmajuk G, Robbins M, Daikh D, Beall A, Yelin E, Barton J et al (2013) Choosing wisely: the American College of Rheumatology’s top 5 list of things physicians and patients should question. Arthritis Care Res 65:329–339CrossRef
23.
Chow SL, Carter Thorne J, Bell MJ, Ferrari R, Bagheri Z, Boyd T, Colwill AM et al (2015) Choosing wisely: the Canadian Rheumatology Association’s list of 5 items physicians and patients should question. J Rheumatol 42:682–689CrossRefPubMed
Metadata
Title
The universe of ANA testing: a case for point-of-care ANA testing
Authors
Konstantin N. Konstantinov
Robert L. Rubin
Publication date
01-12-2017
Publisher
Springer International Publishing
Published in
Autoimmunity Highlights / Issue 1/2017
Print ISSN: 2038-0305
Electronic ISSN: 2038-3274
DOI
https://doi.org/10.1007/s13317-017-0093-6

Other articles of this Issue 1/2017

Autoimmunity Highlights 1/2017 Go to the issue

Original Article

HLA-DQ2 and -DQ8 haplotypes frequency and diagnostic utility in celiac disease patients of Gaza strip, Palestine

Original Article

Detection of autoantibodies to DSF70/LEDGFp75 in Mexican Hispanics using multiple complementary assay platforms

Review Article

Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment

Original Article

Exploring the plasmatic platelet-activating factor acetylhydrolase activity in patients with anti-phospholipid antibodies

Original Article

Structure and activation of the TSH receptor transmembrane domain

Original Article

Definition of the upper reference limit for thyroglobulin antibodies according to the National Academy of Clinical Biochemistry guidelines: comparison of eleven different automated methods
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits